Life Sciences Archive » August, 2015

Life Sciences - August, 2015

316 articles

• Patient In Genzyme Drug Suit Says Class Claims Should Stay
• Full Fed. Circ. Urged To Review Axing Of DNA Test Patent
• Sanctions Bid Accuses Novartis Unit Of Dodging Discovery
• Kyle Bass-Affiliated Group Targets Drug Patents For IPR
• CORRECTED: Skadden Guides Amicus Therapeutics' $847M Biopharm Buy
• Nexium Pay-For-Delay Plaintiffs To Appeal Loss To 1st Circ.
• Data Justified Cymbalta Risk Warnings, Eli Lilly Says
• SAC Slams Class Cert. Bid In Insider Trading Suit
• High Court Lets Ex-Va. Gov. Stay Free Amid Bribery Appeal
• Daiichi Sankyo Shells Out $8.2M In Sex Bias Settlement
• Merck Seeks Stop Of Royalty Payments For Diabetes Patents
• Nature's Way Says Ginkgo Pill Plaintiff Forgot Key Detail
• Epic Research Investors Claim CEO Lied About Credentials
• SEC Upholds Stock Suspensions Over Ebola Claims
• How Concerned Is FDA Over Cybersecurity? Look To Hospira
• Judge Keeps Gray Reed Atty Out Of Medtronic Patent Row
• 5 Insights From 3M General Counsel Ivan Fong
• Using Patents To Secure Repeat Customers
• Collecting Fees Still Tough After Octane, Highmark Cases
• Drug Cos. Win Stay Of False Ad Suit Over Painkiller Safety
• Endo Wants TCPA Suit Held Longer While FCC Mulls Fax Rule
• 2nd Circ. Won't Revive Drug Price Suit Against J&J, Others
• Merck Challenges Pa. Stormwater Permit For Vaccine HQ
• Bayer Must Face Mo. Mirena Suit After Calif. Claims Nixed
• Response Genetics Gets Nod For September Asset Sale
• Texas Court Revives $1.9M Award Over Biotech Patent Project
• Lupin, Allergan Get Support In Pay-For-Delay Fight At 1st Circ.
• Takeda Tells Jury Studies Tying Actos To Cancer Are Flawed
• The Road Ahead For Kyle Bass's IPRs
• Amarin, FDA To Discuss Settling Off-Label Promotion Dispute
• Deals Rumor Mill: Baxalta, Worldpay, Qihoo 360
• Mylan Shareholders Back Takeover As Perrigo Digs In Heels
• Fraud Claims Against Lilly Tossed In Cymbalta Labeling Row
• 5 Dos And Don'ts For Employers After NJ's Ethicon Ruling
• Takeda Hid Link Between Actos And Cancer, Nev. Jury Told
• 340B 'Mega-Guidance' Dials Back Patient Eligibility
• Stanford's Prenatal Testing Patent Appeal Moved To Fed. Circ.
• On Biosimilar Names, FDA Charts Middle Course
• Amgen Wants Biosimilar Halted For Full Fed. Circ. Review
• 7 Benefits Of Arbitration In A Patent Dispute
• Merck KGaA Sells $2.4B In Bonds To Fund Sigma-Aldrich Buy
• Merck Can't Dodge Fraud Case Over Vytorin Trials
• Greatbatch To Buy Lake Region Medical In $1.7B Deal
• 8th Circ. Nixes Jones Day's Training Video Sanction
• Tips For Responding To An FTC Subpoena
• TTAB Reverses Generic Determination For 'Skinsleeves' Mark
• Mylan Calls Apotex's Suit A Bid To Destroy Exclusivity Rights
• Chelsea Therapeutics Class Action Left Intact, With Warning
• Boston Scientific Wants Plaintiff's Murder Plea In Mesh Trial
• Janssen, Celltrion Brawl Over Fed. Circ. Biosimilar Ruling
• Bard Urges Justices To Turn Down Petition In $1B IP Dispute
• Texas Jury Acquits Cancer Agency Exec In $11M Grant Row
• Mylan Nabs AIA Review Of 2 Patents For Teva's Copaxone
• Reckitt Must Face Majority Of Mucinex Monopoly Claims
• Misrepresentation Claim Still Alive In Bayer IUD Liability Suit
• FDA Seizures Don't Negate Layoff Notice Rule: 6th Circ.
• ITC, ClearCorrect Each Say Suprema Backs Its Fed. Circ. Args
• FTC Can't Go Straight To 3rd Circ. In AbbVie Antitrust Fight
• Don't Ignore Small And Midsize Health FCA Settlements
• Unanswered Questions: China's New Pharma Advertising Rule
• PTAB Poised To Take Up Hedge Fund Hijinks In Celgene Cases
• Celgene Says High Court Ruling Limits Length Of FCA Suit
• Fed. Circ. Stands By Shire Claim Construction Ruling
• Eli Lilly Scores Win Over Teva In Alimta Patent Fight
• Plaintiffs Seek New Class Cert. In Supple False Ad Suit
• FTC Loses Reconsideration Bid In AbbVie Pay-For-Delay Suit
• FDA Warning Wire: Device Makers Feel Inspection Heat
• Eli Lilly's IP Suit Defense Based On Typo, Pharma Co. Says
• Insys Pharma Targeted By Group With Ties To Kyle Bass
• Provigil Buyers Say Drug Cos. Twisting Class Cert. Order
• Medtronic Wants Gray Reed Atty Kept Out Of Patent Row
• FDA's Focus On Drug Appearance May Cause Ugly Problems
• Ex-Va. Gov. Gets High Court Reprieve Pending Bail Issue
• Eli Lilly Blasted Over Cymbalta Labeling In Side Effect Row
• Ex-InterMune CEO's Complaints Against Trial Counsel Nixed
• Vitamin C Cos. Say No Concession In Cartel Compulsion Fight
• Medtronic Wins Dismissal Of Remaining Claims In Infuse Suit
• Stubborn FDA Invites Court Fights, Sidley Austin Atty Says
• IBM Inks $115M Boston-Area Sublease For 160K Square Feet
• Hedge Fund Manager Loses IPR Bids Against Acorda
• Medical Device Cos. Didn't Flout Patent, Texas Jury Says
• NJ Judge Axes Design Defect Claims From AlloDerm Suits
• Bankruptcy Code Doesn't Cover Pot Business, 10th Circ. Says
• Amazon Must Face Dangerous Diet Drug Suit, 2nd Circ. Told
• Walgreen, Rite Aid Slam Dismissal Bid in Opana Antitrust MDL
• Pfizer To Shed Four Products For FTC Blessing Of $17B Deal
• Supplement Co. Says 'Tainted' Judge Should Exit FTC Row
• OIG Says Certain Free Drug Starter Programs May Be OK
• FTC Renews Push For Sanctions Against Hi-Tech
• Law360 Pro Bono All Stars Show Dedication To Helping Others
• Bank Can't Collect $10M Fees From Hemispherx: 3rd Circ.
• Amgen Can't Make Journalist Testify In Shareholder Suit
• Savient Investors Lose Suit Over Pre-Bankruptcy Statements
• 20 Firms Show How To Win Big And Do Good
• Post Limelight, Could Patent Act Be More User-Friendly?
• Foreign Drug Smugglers Ordered To Pay $75M
• FTC Says Lax FDA Rules On Homeopathic Drugs Pose Conflict
• Taxation With Representation: Simpson, Shearman, Sullivan
• Judge Sides With Release Of New Covert Fetal Tissue Video
• Drug Cos. Say Loestrin Buyers Trying To Expand Actavis
• Novartis Can't Nix Gleevec Antitrust Suit, Buyers Say
• FTC Says Its Evidence Is Allowed In Robocaller Injunction Row
• The 1st IPR Institution Decisions For Biosimilars
• Amgen, Sandoz Urge Fed. Circ. To Revisit Biosimilar Ruling
• Oakland Loses 9th Circ. Fight To Keep Medical Pot Shop
• Knobbe Martens Dodges DQ Bid In Neovasc Patent Dispute
• Otsuka, Alkermes Trade Fire Over Abilify Maintena Rival
• Merck Wins Patent Dispute Over Cancer Treatment Drug
• Whistleblower Can't Depose Novartis Ex-CEO In FCA Suit
• NJ Judge Trims Sales Rep's FCA Claims In Plavix MDL
• 2 Firms Take Advantage Of Deal-Happy Life Sciences Sector
• Allergan Product-Hopping Suit Nixed On Faulty Assignments
• Pa. Appeals Court Affirms $4M Topamax Verdict
• Ex-Va. Gov. Loses Bid To Stay Free During High Court Appeal
• Purdue Agrees To NY AG's Terms On OxyContin Safeguards
• 6th Circ. Backs Class Cert. In P&G False Ad Action
• Akorn Again Hit With Fraud Suit Over Post-Merger Accounting
• Even The FDA Is Keeping Up With The Kardashians
• Valeant Inks $1B Deal For Female Libido Drugmaker Sprout
• Steris Judge Won't Question FTC's Future-Competition Theory
• Amgen Deal Struck As Tide Turns To Looser Off-Label Limits
• PTAB Won't Institute AIA Review Of Tissue Graft Patent
• Judge In FedEx Drug Case Bashes Prosecutors, Delays Trial
• Biogen Lied In Rosy Growth Forecast, Investor Suit Says
• Ex-Employee Suing Syringe Maker Apologizes For Accusations
• Ethicon Denied Retrial After $3M Bellwether Mesh Verdict
• PharMerica FCA Suit Dismissed Pending Settlement
• Ropes & Gray Settles Patent-Filing Malpractice Suit
• Top 5 Ways To Help A Law Professional Land A Job
• Bayer Can't Escape One-A-Day Labeling Class Action
• Acusphere Fights Celgene's Bid For Atty Fees In Patent Row
• How Teva Will Affect Section 337 Investigations
• Bio-Rad Investor Accuses Board Of Rampant Malfeasance
• Synergy Exec Says Nixed Launch 'Disaster' Not Tied To Merger
• FTC Calls Heath Co.'s UV-Disinfecting Claims Misleading
• Concordia, Par Settle With FTC Over Generic ADHD Drug Deal
• FDA Warning Wire: Mylan, Walgreen, MWT Materials
• 1st Female Libido Treatment Approved By FDA
• Hemispherx Can't Duck Suit Over $2.1M Exec Bonuses
• Prograf MDL Class Cert. Not Doomsday, 1st Circ. Hears
• Real Estate Rumors: Savanna, Eataly, Zoetis
• Amgen Pays $71M In Multistate Drug-Marketing Settlement
• China To Speed Up Drug, Medical Device Approval Process
• Pfizer Limited In Bid For Brualdi Firm Records, Master Says
• Allergan Nears Win Over Miotox's $600M Botox Royalty Claim
• Cherokees Want J&J Risperdal Suit Back In Okla. State Court
• FDA Puts Science Over Politics In Female Libido Pill Review
• Sen. Decries FDA's 'Reckless' Approval Of OxyContin For Kids
• Aggrenox Plaintiffs Say Boehringer's Lidoderm Take Is Wrong
• FTC Tells Court $1.9B Steris Deal Will Curb New Competition
• King & Spalding Adds Prominent Product Liability Litigator
• How Much Money Does It Take To Make A Lawyer Happy?
• Olympus Took Years To Disclose Infections, FDA Says
• Drugmaker Retrophin Sues Ex-CEO For $65M
• Ex-Pfizer Workers Tell 3rd Circ. Benefits Panel Had Conflicts
• Foley & Lardner Adds 2 K&L Gates Life Sciences Partners
• Direct Digital Asks 7th Circ. To Stay Class Cert. For High Court
• Using Social Media To Monitor Postmarket Drug Safety
• Fed. Circ. Urged To Review Toss Of Fetal DNA Test Patent
• Judge Eyes Receivership For 'Derelict' Chinese Vitamin C Cos.
• Actavis, Others Infriged Endo's Opana Patents, Judge Says
• Monopoly Claims Nixed In Solodyn Pay-For-Delay Suit
• Eli Lilly Fights Consolidation Bid For Cymbalta Suit
• FDA Guides Drugmakers On Rare Disease Research
• Texas Justices Pass On Friedman & Feiger Malpractice Row
• Gray Reed Removed From Medtronic Patent Trial In Texas
• Zimmer Expert's Model Survives Attack In Knee Implant MDL
• Merck, Sex Bias Plaintiffs Attempt To Settle Data Row
• No IPOs Ahead As August Slump Mixes With Market Volatility
• Fed. Circ. Asked Not To Revive $15M Award In Prosthetics IP
• Abbott Can't Escape Depakote Birth Defect Claims
• Mylan Fires Back As Proxy Adviser Blasts Perrigo Deal
• Boehringer Says Retailers' Aggrenox Suits Still Must Be Nixed
• Pfizer Gets Canadian Approval For $17B Hospira Takeover
• Mediation — Panacea Or Placebo?
• WuXi PharmaTech To Go Private In $3.3B Deal
• Product-Hopping Cases: A Bad Prescription For Consumers
• J&J's Herpes Test Evidence In Motrin Suit Called 'Speculative'
• Pa. Judge Narrows Class In Provigil Pay-For-Delay Suit
• AbbVie Expands Attack On FDA Biosimilar Labeling
• Deals Rumor Mill: Baxalta, TPG Capital, Femsa
• Forest Labs Jumping Gun In $100M Sex-Bias Suit, Court Told
• 2015 M&A Easily Clears $3T Mark Fueled By Megamergers
• FTC Resolves Claims Over 'Cancer-Detecting' Apps
• Ex-Teva Atty Says Changing Story Dooms Firing Defense
• J&J Units Dodge Sunscreen SPF Labeling Class Action
• J&J Wants Punitives Axed In Philly Pelvic Mesh Cases
• Hagens Berman Asks 3rd Circ. To Revive Thalidomide Suit
• NJ Appeals Court Backs Merck Victory In Vioxx Suit
• McDonnell Asks For Freedom As He Preps High Court Bid
• Judge Cuts 2nd Cymbalta Trial Short With Verdict For Lilly
• King Drug May Chill Voluntary Resolution Of IP Disputes
• Fed. Circ. Won't Rethink AIA Interference Appeals Ruling
• Sheller's Risperdal Doc Suit Against FDA Gets Tossed
• Sandoz Aims to Amend Validity Ruling In Pfizer's Toviaz Suit
• FDA Wins Toss Of Mallinckrodt Suit Over Equivalence Rating
• Abbott Hit With Birth Defect Suit Over Anti-Seizure Drug
• Life Sciences IPOs One Step Ahead Of Market Volatility
• King & Spalding Gets 4 Partners From DLA Piper
• Tax Court Says Chemist Owes $3.8M For Supplement Income
• Novartis Says Docs Request In $3.3B FCA Suit Is Too Late
• Whistleblower GC Pushes To Keep Bio-Rad In Bribery Suit
• No Kickback Penalty For Free Drugs, Inspector General Says
• AbbVie Investor Renews Push To See Books In Failed Merger
• Reckitt Hit With Suit Over Krill Oil Health Claims
• FTC's $2B Steris Merger Fight To Turn On Future Competition
• Amarin Off-Label Promotion Decision: A Watched Pot Boils
• Eli Lilly Faces Second Cymbalta Trial After Bellwether Win
• Roche Still Perfect In Accutane Appeals With Defiant Tactic
• Merck Loses At BALCA Based On Iffy Doctorate Timing
• Robbins Geller Gets $60M In $400M Pfizer Class Action Deal
• GNC Liable For Wage And Break Violations, Workers Say
• Protein Powder Co. Gets Suit Over Label, Ad Content Pruned
• FDA, Amarin Bash Watson's Bid To Join Exclusivity Fight
• Drugmakers Fight FTC Bid For Privileged Antitrust Risk Docs
• FisherBroyles Adds Practicing Physician As Partner
• Fla. Biotech Firm Settles Negligence Claims Against Attys
• FDA Warning Wire: Kim Kardashian, Valeant, Sipra
• Allergan Suit Is SLAPP Retaliation, VC Fund Contends
• 1st Circ. Asked To Uphold Class Cert. In Prograf MDL
• Pitt Sues Stem Cell Licensee Over Unpaid Royalties
• Eli Lilly Gets Expert Testimony Narrowed In Cymbalta Suit
• Fed. Circ. Mulls Suprema's Impact On ITC's Digital Authority
• ITC Overrules Novo's Objection To Baxter Expert Disclosure
• German Insurer Rips Bid To Triple Value Of Bad Blood Case
• Celgene Gets Antitrust Green Light For $7.2B Receptos Deal
• McDonnell Loses 4th Circ. Bid To Reverse Bribery Conviction
• Roche Wins Reversal Of $25M NJ Accutane Verdict
• Quality Metrics May Reduce FDA Inspections For Pharma Cos.
• FTC's Wright Urges Canada To Nix Criminal Pay-For-Delay Plan
• Amarin's Off-Label Victory Opens Door To More Injury Claims
• 3rd Circ. Axes Travelers' $22M Cephalon Drug Marketing Beef
• Tax Court Upholds $1.2M Deficiency On Marijuana Retailer
• Bayer Cipro Label Downplayed Nerve Damage Risk, Suit Says
• 4 Lessons From The FDA's Milestone Device-Hacking Alert
• Ill. Jury Sides With Zimmer In Hip Implant Defect Case
• Humana, Worker Funds Fight To Preserve Pay-For-Delay MDL
• FTC Defends Bid For Review In AbbVie Pay-For-Delay Suit
• Regeneron Hid Docs From USPTO, Judge Finds In Merus Case
• J&J Hit With Levaquin Nerve Damage Suits In Pa. State Court
• Novartis' Dementia Patch Patent Suit Gets Booted
• Suit Slams Vitamin E Maker's 'Healthy Heart' Advertising
• Wachtell Lipton Guides Mallinckrodt In $1.33B Therakos Buy
• Process Patents Are Vital In Biotech — Why Not Extend Them?
• Smith & Nephew Brings $4.5M Contract Case To Fed Court
• Ethicon Can't Shake Consolidation In Mesh Design Defect MDL
• SEC Seeks To Back Former Bio-Rad GC In Firing Suit
• Agilent Backs Request For High Court To Take $52M IP Battle
• Aetna Ordered To Allow Man's Cancer Treatment
• 5 Questions After Amarin's Off-Label Marketing Triumph
• Fed. Circ. Case Could Give ITC Power To Police Web Piracy
• Fed. Circ. Revives J&J Unit's Patent Case Against Covidien
• Eli Lilly Defeats Cymbalta Risk Claims In Bellwether Trial
• Product Liability Cases To Watch In The Second Half Of 2015
• Gibson Dunn Adds Two IP Litigators from WilmerHale
• Law Trio Aid $242M Loan For Proposed NYC Proton Facility
• 5 Cos. Set Sights On $552M As IPO Market Wavers
• Generic Pharma Co. Pushes Fed. Circ. To Revive Avanir IP Row
• Taxation With Representation: Ropes, Davis, Shearman
• Alaska Says Lupin Pay-For-Delay Probe No Fishing Expedition
• King Drug Decision May Be A Turning Point In Pay-For-Delay
• 2nd Circ. Won't Reconsider Landmark Product-Hopping Ruling
• The Circuits Clash Over Class Action Ascertainability
• Cardinal Health, Owens & Minor Win $1.2B DLA Contract Mods
• FDA's Off-Label Marketing Rules Take Hit In Amarin Fight
• Medtronic Recalls Part Of Newly Approved Heart Device
• Allergan Latest To Reveal DOJ Generic-Drug Price Probe
• 9th Circ. Sends 5 Merck Diabetes Drug Suits To State Court
• Latham Steers $160M Debut Of Allergy Biotech Aimmune
• Precision Medicine Raises More Questions Than Answers
• Ethicon Targets Plaintiff's Evidence Ahead Of Mesh Trial
• PTAB Won't Nix Drug Delivery Patent In AIA Review
• AstraZeneca Sues Chinese Co. To Block Generic Nexium
• UK Watchdog Says Pfizer Overcharged For Epilepsy Med
• Eli Lilly's Cymbalta 'Poison,' Ex-User Says In Bellwether
• Mass. Marijuana Advocates Seek Pot Legalization Vote
• Eli Lilly Says Plaintiff Doesn't Own Patent In Cialis Dispute
• Munck Wilson Adds Ex-Baker Botts Commercial Litigator
• Eli Lilly Slams Cymbalta Plaintiff Ahead Of Trial
• GSK Wants More Info On Expert For Widow Of Reed Smith Atty
• Decertification Appealed In Wellbutrin Pay-For-Delay Suit
• Iodine Product Isn't Diet Supplement, Seller Tells Court
• Pa. Judge Won't Rethink Denial Of Provigil Buyers' Class Cert.
• Takeaways From Delaware's 'New Low' In Flawed Valuation
• Lessons From 5 Years Of Public Interest Delegation At ITC
• Kirkland, Mylan Lay Down Arms In Teva Representation Fight
• Eli Lilly Hid Cymbalta Risks, Jury Told As Bellwether Opens
• Supplement Cos. Ordered To Stop Production Over Impurities
• Philly Court Proves Its Mettle Crafting Nationwide Yaz Deal
• 3rd Circ. Urged To Rethink Lamictal Pay-For-Delay Ruling
• SIGA Says It Needs Time To Keep Ch. 11 Talks On Track
• Celgene Prices $8B Note Offering To Back Receptos Deal
• FDA Warns Novartis' MS Drug Carries Risk Of Brain Infection
• TPP Sputter Brings Political Obstacles Into Focus
• Judge Slams Pretrial 'Squabbles' In $3.35B Novartis FCA Suit
• Evanston Says It Needn't Cover Fat-Burning Supplement Suit
• Class Cert. Sought In J&J 'Natural' Baby Wash False Ad Suit
• Fed. Circ. Denies Nautilus En Banc Review Of Biosig Case
• Pfizer, Zoetis Must Face Poultry Vaccine Suit In Pa.
• Fed. Circ. Affirms Allergan Win In Generic Lumigan Suit
• Bayer Agrees To $57M Deal To End Yaz Blood Clot Suits
• Overcoming Restriction Requirements On Pharma Patents
• Shire Lobs $30B Unsolicited Offer For Baxalta
• Zimmer Hit With $9.2M Verdict In Hip Implant Defect Suit
• IP Firm Denied Chance To Improve On Its Malpractice Victory
• AstraZeneca Can't Stop Mylan's Generic Nexium At Fed. Circ.
• Galderma Owes NYU's Fees For Oracea Appeal, Judge Says
• Depomed, Horizon File Competing Suits In Takeover Battle
• Lupin's Generic Colitis Drug Infringes Patents, Pharmas Say
• Feds Want Foreign Pill Smugglers Fined Nearly $50M
• Top Product Liability Verdicts In The First Half Of 2015
• AbbVie Slams FTC's Bid To Review Pay-For-Delay Ruling
• FDA Warns Hospira Pump Fails Cybersecurity Tests
• OPINION: Bipartisan Trade Secrets Legislation Is Back
• RICO Suits Challenge Off-Label Drug Marketing
• Trade Ministers Fail To Break TPP Deadlock